Synexus opens new Bulgarian site for secondary care trials

By Gareth Macdonald

- Last updated on GMT

Related tags Eastern europe

Synexus' new trial site in Bulgaria, which is part of the firm’s clinical research centre strategy, will help sponsors cut development times and significantly reduce costs, according to CEO Michael Fort.

Fort told in-PharmaTechnologist that the Sophia centre, which will be run by leading clinician Borislav Borissov, expands Synexus’ Bulgarian network and enables the firm to add secondary care trials to its existing primary care offering.

While Synexus is not the only trials firm to be operating in Eastern Europe, both PPD and Covance have recently bolstered their local presences in recent months, the UK firm believes it has adopted a unique strategic approach to making the best of the advantages offered by the region.

Fort said that while trials in Eastern Europe provide cost savings compared with Western Europe, they are less significant than those provided by having a single research centre capable of handling hundreds of patients rather than many trial sites managing few .

For example a major pharma shared with us some figures involving a major trial that are revealing​,” said Fort explaining that the company in question had spent $17m on setting up investigator sites, 60 per cent of which recruited one patient or less.

We have verified these figures with several other pharmas and CROs who found them in line with their own experience. So with one contract for hundreds, and increasingly thousands, of patients Synexus offers huge savings​.”

He also said that eastern Europe offers a much large pool of treatment naive patients than Western Europe and added that Synexus plans to “substantially increase” its number of trial sites in the region.

In terms of the Synexus’ global trials presence, Fort explained that: “We are already in India and are presently looking at a number of further opportunities. We have not yet entered China and while we have no immediate plans we are l[examining] a couple of possibilities​.”

However we have a lot on our plate as we are already aggressively expanding in Europe, India and Africa with several announcements scheduled in the next six months​.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more